Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| IT7-C52W4 | Cynomolgus | Cynomolgus Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free (MALS verified) |
|
|
|
| EP-155 | Human | Integrin α 4 β 7 : MAdCAM-1 [Biotinylated] Inhibitor Screening ELISA Kit | |||
| IT7-H52W4 | Human | Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free (MALS & SPR verified) |  |
|
|
Human MAdCAM-1, Fc Tag (Cat. No. MAM-H5253) captured on Protein A Chip can bind Cynomolgus ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-C52W4) with an affinity constant of 5.77 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Pediatric ulcerative colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Gastritis; Urogenital Neoplasms; Colitis, Ulcerative; Cholangitis, Sclerosing; Celiac Disease; Solid tumours; Colitis; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; HIV Infections; Hematopoietic stem cell transplantation (HSCT) | Details |
| Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Myositis, Inclusion Body; Demyelinating Diseases; Ischemic Stroke; Crohn Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Pouchitis; Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 3 Clinical | Alvotech Swiss Ag | Immune System Diseases; Colitis, Ulcerative | Details |
| Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | Details |
| MORF-057 | MORF-057 | Phase 2 Clinical | Morphic Therapeutic Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
| PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
| GS-1427 | GS-1427 | Phase 2 Clinical | Gilead Sciences Sl | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
| ABBV-382 | ABBV-382 | Phase 2 Clinical | Abbvie Inc | HIV Infections; Crohn Disease | Details |
| PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
| EA-1080 | NSHO-101; EA-1080 | Phase 1 Clinical | Ea Pharma | Inflammatory Bowel Diseases | Details |
| SPY-001 | SPY001; SPY-001; PR-011; PR011; SPY001-001 | Phase 1 Clinical | Paragon Therapeutics Inc | Inflammatory Bowel Diseases | Details |
This web search service is supported by Google Inc.
A-Z
